Oncolytics Biotech Inc. (ONCY)
0.58
0.01 (2.36%)
At close: Apr 24, 2025, 3:59 PM
0.58
0.66%
After-hours: Apr 24, 2025, 07:28 PM EDT
2.36% (1D)
| Bid | 0.55 |
| Market Cap | 49.91M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -31.71M |
| EPS (ttm) | -0.3 |
| PE Ratio (ttm) | -1.92 |
| Forward PE | -1.35 |
| Analyst | Buy |
| Ask | 0.63 |
| Volume | 360,013 |
| Avg. Volume (20D) | 379,377 |
| Open | 0.57 |
| Previous Close | 0.57 |
| Day's Range | 0.54 - 0.58 |
| 52-Week Range | 0.47 - 1.53 |
| Beta | 1.55 |
About ONCY
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 5, 2001
Employees 28
Stock Exchange NASDAQ
Ticker Symbol ONCY
Analyst Forecast
According to 3 analyst ratings, the average rating for ONCY stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 765.80% from the latest price.
Stock Forecasts2 weeks ago
+24.56%
Oncolytics Biotech shares are trading higher after...
Unlock content with
Pro Subscription
6 months ago
+18.22%
Oncolytics Biotech shares are trading higher after the company announced key progress and upcoming studies for breast and pancreatic cancer treatments while also preparing for an accelerated FDA approval path.
